White Paper
The Impact of Formulary Controls on Medicare Patients in Five Chronic Therapeutic Areas
Jun 16, 2025
To understand how payer controls may impact Medicare Part D patients, we conducted an in-depth, longitudinal study of payer rejections occurring January 2020 through September 2024 across five chronic therapeutic areas (TAs) — pulmonary arterial hypertension (PAH), osteoporosis, multiple sclerosis (MS), immunology, and migraine. Top brands, as determined by market share, within each TA were selected for analysis.

Related solutions

Contact Us